Metformin for the Treatment of Endometrial Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- The University of North Carolina at Chapel Hill
-
Southern Pines, North Carolina, United States, 28388
- Southern Pines Women's Health Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be between the ages of 18-75 years old
- Have a confirmed diagnosis of endometrial hyperplasia without atypia based upon endometrial biopsy
- Have no contraindications to short-term metformin therapy
- Have a creatinine clearance of ≥ 90 ml/min, as calculated by the Cockroft-Gault formula
- Have normal serum transaminase values (AST and ALT)
- Need to be able to undergo metformin treatment for a duration of 12 weeks prior to repeat endometrial biopsy
Exclusion Criteria:
- Are currently taking metformin or have taken metformin in the past 6 months or have a history of an allergic reaction or intolerance at any time to metformin
- Have a history of liver or renal dysfunction.
- Have a random glucose of ≤ 65 or ≥ 200
- Have a recent history of alcoholism. Former alcoholics who have abstained from alcohol for 5 years or more may be enrolled in this study.
- Have a history of vitamin B12 deficiency
- Are pregnant
- Are currently taking insulin
- Are taking a drug that may significantly interact or influence the metabolism of metformin
- In the opinion of the investigator, the patient is felt not to be appropriate for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Metformin
Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
|
850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response Rate
Time Frame: 12 weeks
|
Evaluation of hyperplasia resolution by comparison of pre- and post-treatment endometrial biopsies.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Toxicity evaluation
Time Frame: 12 weeks
|
Number of subjects who experience side effects
|
12 weeks
|
|
Patient Compliance
Time Frame: 12 weeks
|
Percentage of patients successfully completing metformin therapy.
|
12 weeks
|
|
Potential molecular markers in response to treatment with Metformin
Time Frame: 12 weeks
|
Compare changes in potential biomarkers, including metabolic factors and molecular markers of downstream targets of the metformin/mTOR signaling pathway, before and after metformin treatment.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Victoria Bae-Jump, MD, PhD, University of North Carolina, Chapel Hill
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LCCC 1205
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.